Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy
Hoolachan, Joseph M.
Hammond, Suzan M.
de Jong, Olivier G.
Wood, Matthew J.A.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Nervous System Diseases
Neuroscience and Neurobiology
MetadataShow full item record
AbstractSpinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify potentially novel treatments to alleviate muscle pathology combining transcriptomics, proteomics, and perturbational data sets. This revealed potential drug candidates for repurposing in SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including lifespan, weight, and key molecular networks in skeletal muscle. Our work highlights the potential of multiple and parallel data-driven approaches for the development of potentially novel treatments for use in combination with SMN restoration therapies.
Meijboom KE, Volpato V, Monzón-Sandoval J, Hoolachan JM, Hammond SM, Abendroth F, de Jong OG, Hazell G, Ahlskog N, Wood MJ, Webber C, Bowerman M. Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight. 2021 Jul 8;6(13):e149446. doi: 10.1172/jci.insight.149446. PMID: 34236053; PMCID: PMC8410072. Link to article on publisher's site